Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
Furthermore, the cohort of participants who tolerated initial treatment with 10mg or 15 mg tirzepatide may not be fully representative of the general population, as many patients may experience side effects at lower doses, or have preexisting conditions that may affect their tolerance
professional bodies now highlight that working with a dietitian can maximise GLP1 results and protect nutrition in diabetes care
Quick Answer: There is no clinical evidence that one time of day is more effective for weight loss than another
For support: [email protected] or [email protected] for order-related concerns
If it's not the right fit, we'll tell you, and point you toward what is often our medically supervised weight loss program
)
